On June 17, 2024, the Board of Directors of Entero Therapeutics, Inc. after discussions with Jack Syage, the Company?s President, Chief Operating Officer and a member of the Board, transitioned Dr. Syage from the role of Chief Operating Officer to the newly appointed role of Chief Scientific Officer, effective immediately. Dr. Syage will continue to serve as the Company?s President and report to James Sapirstein, the Company?s Chief Executive Officer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9801 USD | -12.49% | -45.55% | -76.66% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-76.66% | 2.43M | |
+17.72% | 44.87B | |
-10.33% | 37.8B | |
+42.32% | 37.61B | |
+29.36% | 31.32B | |
-8.44% | 27.4B | |
+12.45% | 26.32B | |
+44.19% | 14.07B | |
+31.93% | 12.5B | |
-7.67% | 11.23B |
- Stock Market
- Equities
- ENTO Stock
- News Entero Therapeutics, Inc.
- Entero Therapeutics, Inc. Announces Transition of Jack Syage from Chief Operating Officer to Chief Scientific Officer